ONCOLOGY Editorial Advisory Board Member Dies from Glioblastoma

Fact checked by" Tim Cortese
News
Article

Edward Chu, MD, a member of the gastrointestinal editorial advisory board, died of glioblastoma in November.

Edward Chu, MD, a member of the ONCOLOGY gastrointestinal editorial advisory board, died of glioblastoma in November.

Edward Chu, MD, a member of the ONCOLOGY gastrointestinal editorial advisory board, died of glioblastoma in November.

Edward Chu, MD, MMS, died of glioblastoma on November 13th, at age 66.1 Chu was the vice president of Cancer Medicine and the Carol and Roger Einger Professor of Cancer Medicine at Montefiore Einstein Comprehensive Cancer Center. He was also a gastrointestinal editorial advisory board member for the journal ONCOLOGY®.

Chu joined Montefiore in 2020, where his work significantly contributed to the growth of the cancer center, which resulted in a comprehensive status designation by the National Cancer Institute (NCI) in 2023. At the time, this institution followed only 55 others in the US who had received this status.2

“This NCI designation is a testament to the remarkable strength of our exceptional science integrated with extraordinary multidisciplinary patient care,” Chu said at the time of designation.2

After finishing his fellowship with the NCI, Chu began working at Yale School of Medicine in 1996 and was named the deputy director of Yale Cancer Center in 2007.3 In 2010, Chu moved to The University of Pittsburgh Medical Center Hillman Cancer Center and was the deputy director, chief of the Division of Hematology-Oncology, co-leader of the Cancer Therapeutics Program, and director of the Phase I Program until his move to Montefiore in 2020.

Chu began his contributions to the journal ONCOLOGY in 2003. His most important contributions included:

Chu is remembered by his colleagues for his passion, sharp mind, deep laugh, and generous spirit.1 CancerNetwork and the journal ONCOLOGY offers condolences to Chu’s wife, Laurie Harrold, MD, and his children Ashley and Josh Chu.

References

  1. Edward Chu Obituary. The New York Times. November 16, 2025. Accessed December 1, 2025. https://tinyurl.com/58mtt8km
  2. Montefiore Einstein Comprehensive Cancer Center awarded Comprehensive Designation from the National Cancer Institute. News release. Montefiore Einstein. September 12, 2023. Accessed December 1, 2025. https://tinyurl.com/2yu7ctrn
  3. Montefiore Einstein Director Edward Chu dies of glioblastoma at 66. News release. November 21, 2025. Accessed December 1, 2025. https://tinyurl.com/48ty8wfw

Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.
Using chlorotoxin as a targeting element may bind to more glioblastoma cells than other targeting entities, according to Michael Barish, PhD.
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.